• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs - Real World Outcomes >Efficacy of Low-Dose Oral Liquid Morphine for Elderly Patients with Chronic Non-Cancer Pain: Retrospective Chart Review
【24h】

Efficacy of Low-Dose Oral Liquid Morphine for Elderly Patients with Chronic Non-Cancer Pain: Retrospective Chart Review

机译：低剂量口服吗啡对老年慢性非癌性疼痛患者的疗效：回顾性图表回顾

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction The use of medications among older persons can often be challenging as physiological changes may affect metabolism and cognitive abilities. Several studies show that the elderly with chronic pain are seriously undertreated or inappropriately treated, particularly with respect to opioids. Objective To determine whether very low doses of oral liquid morphine (LM) in patients over 65?years of age with chronic non-cancer pain provides meaningful pain improvement. Methods A retrospective chart review was conducted for ten carefully selected older patients seen at a tertiary care pain clinic in Toronto Ontario (2009–2011) with serious biomedical painful conditions and intolerance to other opioid analgesics. Data collected included demographics, LM dosing, diagnosis and average Numeric Rating Scale (NRS) pain ratings pre- and post-administration of LM. Results Of the ten eligible patients, the female/male ratio was 4:1, mean age 75.5?years and mean pain duration 7.9?years. The initial dose of LM for all patients was 1–3?mg three times/day and the maintenance dose ranged from 5 to 30?mg/day. Overall, pain ratings dropped from 6.35 to 2.95 (3.4 point drop on the NRS score) with a mean follow-up of 14?months (range 10–21). Conclusion The case series showed that carefully selected elderly patients with biomedical pathology can benefit from very low doses of LM. Future larger and well-designed studies need to focus on the use of LM for elderly patients.
机译：简介由于生理变化可能影响新陈代谢和认知能力，因此在老年人中使用药物通常可能具有挑战性。多项研究表明，患有慢性疼痛的老年人受到严重的治疗不足或治疗不当，尤其是在阿片类药物方面。目的确定在65岁以上的慢性非癌性疼痛患者中使用非常低剂量的口服吗啡（LM）是否可以有意义地改善疼痛。方法对十名经过精心挑选的老年患者进行回顾性图表回顾，这些患者是在安大略省多伦多的一家三级医疗疼痛诊所（2009-2011年）发现的，这些患者患有严重的生物医学疼痛且对其他阿片类镇痛药不耐受。收集的数据包括人口统计学，LM给药，诊断以及LM给药前后的平均数字评分量表（NRS）疼痛评分。结果10例合格患者中，男女之比为4：1，平均年龄75.5岁，平均疼痛持续时间7.9岁。所有患者的LM初始剂量为1-3次/天，每天3次，维持剂量为5-30毫克/天。总体而言，疼痛评分从6.35降至2.95（NRS评分下降3.4点），平均随访14个月（范围10-21）。结论该病例系列表明，精心选择的具有生物医学病理学特征的老年患者可从极低剂量的LM中获益。未来更大且设计合理的研究需要集中于老年患者使用LM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号